What is HC Wainwright’s Forecast for Savara FY2027 Earnings?

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday, December 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.18). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2028 earnings at $0.13 EPS.

Other analysts have also recently issued reports about the stock. UBS Group set a $10.00 target price on shares of Savara in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Wednesday, October 8th. Oppenheimer set a $10.00 price objective on Savara in a research report on Tuesday. JMP Securities lifted their target price on Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, October 23rd. Finally, Wells Fargo & Company increased their price target on Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Savara Price Performance

Savara stock opened at $6.40 on Thursday. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm’s fifty day moving average is $5.12 and its 200 day moving average is $3.66. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -12.07 and a beta of 0.23.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Prudential Financial Inc. bought a new stake in shares of Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the period. May Hill Capital LLC bought a new stake in shares of Savara during the second quarter worth $32,000. Brevan Howard Capital Management LP bought a new stake in shares of Savara during the second quarter worth $33,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after purchasing an additional 9,463 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.